Navigation Links
Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights
Date:7/30/2009

crease in basic and diluted net loss per share for the second quarter of 2009 and 2008, respectively.

For the six months ended June 30, 2009, Anadys reported a net loss of $15.3 million, compared to $14.5 million for the same period last year. Basic and diluted net loss per common share was $0.51 for the six months ended June 30, 2009 and 2008.

Operational Highlights

  • Closed Registered Direct Financing. In early June, Anadys closed a "registered direct" offering through the sale of units to institutional investors, with each unit consisting of one share of common stock and a warrant to purchase 0.35 of a share of common stock. $17.5 million in gross proceeds were raised, with net proceeds of approximately $16.0 million, after deducting placement agent fees and estimated offering expenses. Proceeds from the transaction are being used to further the development of ANA598, as well as for other general corporate purposes.
  • Future Operations to Focus on Development of ANA598. In June, Anadys initiated a strategic restructuring to focus its operations on the continued development of ANA598, in particular a Phase II study in combination with pegylated interferon-alpha and ribavirin. The restructuring included a reduction in Anadys' workforce expected to generate annual savings of $4 to $5 million, while retaining the clinical development infrastructure required to conduct the Phase II study of ANA598, key capabilities directed toward pharmaceutical development and next generation non-nucleosides, and a streamlined administrative staff. Also included in the restructuring is an expected reduction in annual facility expense of approximately $1.8M associated with our completed move to a smaller facility.

Development Program Highlights

ANA598

ANA598 is the Company's non-nucleoside H
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Anadys Pharmaceuticals to Report Second Quarter 2009 Financial Results
2. Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598
3. Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights
4. Anadys Pharmaceuticals to Report First Quarter 2009 Financial Results
5. Anadys Pharmaceuticals to Present at Future Leaders in the Biotech Industry
6. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
7. Anadys Pharmaceuticals to Present at the Needham Focus on Infectious Disease Conference
8. Anadys Pharmaceuticals to Present at Rodman & Renshaw Annual Global Investment Conference
9. Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients
10. Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
11. Anadys Pharmaceuticals to Present at BIOCOM Investor Conference 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 21, 2014 2014 Deep Research ... is a professional and in-depth research report on ... information, like its definition, classification, application, and ... This report covers the international market analysis, including ... as the US, Europe, Asia, China, Japan etc. ...
(Date:11/21/2014)... 20, 2014 Polaris Group announced today ... its Phase 1 trial of ADI-PEG 20 in ... of malignant pleural mesothelioma (MPM) and non-squamous non-small ... trials on ADI-PEG 20, both as monotherapy and ... of several other indications, including breast cancer, melanomas, ...
(Date:11/21/2014)... , Nov. 20, 2014  Cytori Therapeutics (NASDAQ: ... Hedrick , M.D. will present live at VirtualInvestorConferences.com on December ... TIME:    11:15 am PT / 2:15 pm ET ... into your browser,s address bar: http://bit.ly/1B2KGaL ... receive event updates. This will be a ...
(Date:11/18/2014)... 18, 2014 Cord Blood Registry® (CBR®) ... 10th Annual World Stem Cell Summit, the largest global meeting ... World Stem Cell Summit will be held December 3-5 at ... . The World Stem Cell Summit ... cures and therapies, convening the most prominent figures in the ...
Breaking Biology Technology:Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 2Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 3Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 2Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 3Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 4Cord Blood Registry Sponsors 2014 World Stem Cell Summit 2Cord Blood Registry Sponsors 2014 World Stem Cell Summit 3
... May 24, 2012  Novocure™, a commercial stage private oncology ... centers of excellence will join the seven existing clinical ... to patients with recurrent GBM. These fifteen clinical centers ... GBM is both the deadliest and ...
... NEW YORK, May 23, 2012 Exosome Diagnostics, ... for use in personalized and non-invasive cancer diagnostics, ... utility of non-invasive sampling of patients, urine to ... In the first study, the presence of a ...
... imaging system that scans 3D models of historical buildings using ... a human pilot onboard. This is the first 3D imaging ... technologies, and virtual representation of models to produce a realistic ... this project is to obtain a 3D model of a ...
Cached Biology Technology:Novocure™ Certifies Eight Additional Clinical Centers of Excellence to Treat Most Common Brain Tumor with Tumor Treating Fields (TTFields) Therapy 2Novocure™ Certifies Eight Additional Clinical Centers of Excellence to Treat Most Common Brain Tumor with Tumor Treating Fields (TTFields) Therapy 3Novocure™ Certifies Eight Additional Clinical Centers of Excellence to Treat Most Common Brain Tumor with Tumor Treating Fields (TTFields) Therapy 4Exosome Diagnostics Presents Data at American Urology Association Demonstrating Potential Utility of Urine Exosomes to Non-invasively Detect and Manage Prostate Cancer 2Exosome Diagnostics Presents Data at American Urology Association Demonstrating Potential Utility of Urine Exosomes to Non-invasively Detect and Manage Prostate Cancer 3A new imaging system produces 3-D models of monuments using unmanned aircraft 2
(Date:11/5/2014)... RENO – Kelly Redmond has dedicated his career ... knowledge to a general audience. , As deputy ... Climate Center at Nevada,s Desert Research Institute, Redmond ... the management, application and dissemination of climate data ... Annual Fall Meeting in San Francisco on December ...
(Date:11/4/2014)... Fla. (November 4, 2014) — Think about the way ... How do neighboring cells know that they are supposed ... how do these tissues find the correct place and ... answering these crucial questions. , In a new study, ... to communicate with their surrounding neighbors, at the head-trunk ...
(Date:11/3/2014)... , Nov. 3, 2014 Research and ... "Cell Therapy - Technologies, Markets and Companies" to ... cell therapy technologies and methods, which have already started to ... stem cell transplantation is replacing the old fashioned bone marrow ... Cell therapy is bound to become a part of medical ...
Breaking Biology News(10 mins):Nevada climatologist to be honored at AGU Fall Meeting for lifetime of public outreach 2The inside story: How the brain and skull stay together 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3
... Fla. -- Leading Florida-based scientific researchers released two new ... that climate change will cause significant impacts on Florida,s ... A second study by researchers at Florida Atlantic University ... of policy programs aimed at adapting to these large ...
... researchers have found that the main source of food for ... appears to adapt in order to survive climate change. ... are just a few millimetres in size, live in the ... out. It showed they responded to global warming after ...
... & Commerce, WALL, N.J., Sept. 23 ... in finger-based biometric,identification and wireless public safety, announced ... Technology Expo, to be held in,conjunction with the ... 25 at the Tampa Convention Center in Tampa, ...
Cached Biology News:New studies find global warming will have significant economic impacts on Florida coasts 2New studies find global warming will have significant economic impacts on Florida coasts 3Researchers find animal with ability to survive climate change 2BIO-key(R) to Showcase Biometric Security Applications at 2008 Biometric Technology Expo 2BIO-key(R) to Showcase Biometric Security Applications at 2008 Biometric Technology Expo 3
... recognizes 30% of IgM-rheumatoid factor ... does not cross-react with IgM, IgA, ... nor with pooled F(Ab)2 fragments. This ... to detect rheumatoid factor. Product Category: ...
...
Salmonella typhimurium Immunogen: Heat inactivated bacterial cells of Salmonella typhimurium B Storage: 4 C...
...
Biology Products: